What did @chanelica.r actually say?
Chanel spent 15 weeks on brand-name Mounjaro before switching to compounded tirzepatide, which she calls "Compound Chasapatide" throughout the video. Her core claim: she lost 12 pounds in eight weeks on the compound version, compared to 2.8 pounds in her final month on Mounjaro and 4.4 pounds the month before that. She concludes the compound version has been treating her better, cites no injection site pain, and then drops a referral link and coupon code for a provider called Ramp Care. That last part matters, and we will come back to it.
To be clear about terminology: "Chasapatide" is not a drug name. The active ingredient in both Mounjaro and compounded versions is tirzepatide, a dual GIP and GLP-1 receptor agonist. The brand name confusion does not affect the core comparison she is making, but it is worth noting for anyone trying to research this further.
Does the science back this up?
The weight loss numbers she is reporting are plausible given tirzepatide's trial data, but her direct comparison between Mounjaro and the compound version is not a controlled experiment. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. Monthly averages varied considerably across that period.
Here is the problem with her comparison: she likely changed doses, changed her diet, changed her activity level, or all three when she switched products. Weight loss on GLP-1 and GIP agonists is not linear. Early months often produce faster loss as the body adjusts. Her "better results" on the compound may simply reflect normal dose escalation timing, not a product quality difference.
There is also a documented plateau effect. Wilding et al. (2021, NEJM) showed semaglutide results slowing in later weeks. The same pattern applies to tirzepatide. Losing only 2.8 pounds in her last Mounjaro month could reflect plateau, not product inferiority.
What did they get wrong (or right)?
She got the general experience right. Tirzepatide, whether brand or compounded, does produce meaningful weight loss for many people, and injection site reactions are genuinely less common than with some other injectables when administered correctly.
What she got wrong, or at minimum oversimplified, is the implied equivalency claim. When she says "I did not have weight loss like this previously on Monjaro," she is treating the compound version as if it is a superior product. The FDA has been explicit that compounded drugs are not the same as FDA-approved drugs. Compounded tirzepatide does not have the same manufacturing standards, sterility testing, or bioavailability data as Mounjaro or Zepbound. That is not a small caveat.
The referral link and coupon code at the end cross into territory that requires scrutiny. Paid or incentivized promotions for telehealth providers require FTC disclosure. She does not use the word "ad" or "sponsored" anywhere in the transcript. That is a compliance gap, not a medical one, but it shapes how viewers should weigh her enthusiasm.
What should you actually know?
Compounded tirzepatide exists in a complicated legal space. The FDA allows compounding of tirzepatide while it remains on the shortage list, but that status can change. The FDA issued a notice in early 2024 that Zepbound and Mounjaro shortages were being resolved, which would affect compounding legality. Anyone using compounded tirzepatide should verify current shortage status with their provider.
Individual results like Chanel's are real, but they are not evidence that one formulation outperforms another. Her n equals one, and her comparison months were not controlled for dose, diet, or lifestyle. A 2023 analysis by Rubino et al. in Nature Medicine confirmed that tirzepatide produces substantial weight loss, but also showed wide individual variation, meaning some people plateau earlier or respond less robustly at certain doses.
If you are considering compounded tirzepatide, the questions to ask your provider are about the compounding pharmacy's accreditation, the base formulation used, and current FDA shortage status. Do not choose a provider because someone on TikTok has a coupon code.